CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01614093
NCT01614093Phase 4Completed
CompareCT.gov

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

University of Maryland, Baltimore·interventional·Posted Jun 7, 2012·Updated Aug 28, 2019

In Brief

A Phase 4 clinical trial evaluating Oxytocin and Placebo for Schizophrenia. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report) compared to placebo. If this single dose pilot paradigm shows an increase in satiety, it may be tested in follow-up studies as a prevention or treatment for weight gain and overeating in people with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2012
Enrollment StartJun 1, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.1 years ago

Interventions

Oxytocindrug

Single dose intranasal oxytocin (24 IU)

Placebodrug

Placebo- Sugar pill